English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

We gratefully acknowledge the cooperation of officials from the U.S. Bureau of Labor Statistics, in particular Commissioner Katharine Abraham, as well as Assistant Commissioner John M. Galvin, Irwin Gerduk, and Douglas Kanoza in the Office of Industrial Prices and Dennis Fixler, Division of Price and Index Number Research. We have also benefited from the timely and able research assistance of Gillian Currie and Mark Moore. We thank Martin Baily, Stan Finkelstein, Richard Frank, Theodore Keeler, Peter Reiss, Jack Triplett, and Cliff Winston for comments. Research support from the National Science Foundation, the U.S. Bureau of Economic Analysis, the Alfred P. Sloan Foundation, and Eli Lilly Inc. is gratefully acknowledged, as is the considerable data support from Stephen Chappell and Robert Plefka at IMS International and from Rhea Mihalison, Phyllis Rausch, Ditas Riad, and Paul Snyderman at Merck & Co. The opinions and conclusions expressed in this paper are those of the authors and do not necessarily reflect views or positions of any of the organizations with which the authors are affiliated or those of any of the research sponsors.

Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs